AbbVie Inc. (FRA:4AB)
Germany · Delayed Price · Currency is EUR | Market Cap | 315.42B |
| Revenue (ttm) | 49.67B |
| Net Income (ttm) | 3.17B |
| Shares Out | n/a |
| EPS (ttm) | 1.79 |
| PE Ratio | 99.50 |
| Forward PE | 15.91 |
| Dividend | 5.86 (3.28%) |
| Ex-Dividend Date | Jul 15, 2025 |
| Volume | n/a |
| Average Volume | 138 |
| Open | 178.00 |
| Previous Close | 177.40 |
| Day's Range | 177.40 - 179.80 |
| 52-Week Range | 147.00 - 203.05 |
| Beta | n/a |
| RSI | 56.16 |
| Earnings Date | Oct 29, 2025 |
About AbbVie
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer... [Read more]
Financial Performance
In 2024, AbbVie's revenue was $56.33 billion, an increase of 3.71% compared to the previous year's $54.32 billion. Earnings were $4.24 billion, a decrease of -12.07%.
Financial numbers in USD Financial StatementsNews
AbbVie Inc. (ABBV) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
AbbVie Inc (ABBV) Launches "The One & Only" Campaign for BOTOX® Cosmetic | ABBV ...
AbbVie Inc (ABBV) Launches "The One & Only" Campaign for BOTOX® Cosmetic | ABBV stock news
BOTOX® Cosmetic (onabotulinumtoxinA) Unveils "The One & Only" Campaign Featuring Real People and Their Distinctive Stories
Building on the brand's 20-year legacy and real-world experience, the original BOTOX® Cosmetic continues to be the most researched and requested product of its kind.1,2 BOTOX® Cosmetic is trusted by a...
Glenmark Pharma shares jump over 2% after its subsidiary gets $700 million from AbbVie for licensing deal
Glenmark Pharma shares jumped over 2% in early morning trade after the company announced that its wholly owned subsidiary, Ichnos Glenmark Innovation (IGI), has received an upfront payment of $700 mil...
Glenmark Pharma receives $700 million upfront payment from AbbVie for global licensing deal
Glenmark Pharmaceuticals announced that its wholly owned subsidiary, Ichnos Glenmark Innovation (IGI), has received an upfront payment of $700 million from AbbVie (NYSE: ABBV). The payment follows thr...
Calls of the Day: Abbvie, Vertex, Veeva and Vistra
The Investment Committee discuss the latest Calls of the Day.
Calls of the Day: Abbvie, Vertex, Veeva and Vistra
The Investment Committee discuss the latest Calls of the Day.
1 Reason Every Investor Should Know About AbbVie (ABBV)
This company's past ability to extend patent-protected market exclusivity for its drugs bodes well for new investors.
AbbVie Inc (ABBV) Declares Quarterly Cash Dividend | ABBV stock news
AbbVie Inc (ABBV) Declares Quarterly Cash Dividend | ABBV stock news
AbbVie (ABBV) Maintains Dividend with 3.08% Yield
AbbVie (ABBV) Maintains Dividend with 3.08% Yield
AbbVie declares $1.64 dividend
AbbVie Declares Quarterly Dividend
NORTH CHICAGO, Ill. , Sept. 5, 2025 The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.64 per share.
Here's How Much You Would Have Made Owning AbbVie Stock In The Last 5 Years
AbbVie (NYSE: ABBV) has outperformed the market over the past 5 years by 4.54% on an annualized basis producing an average annual return of 18.62%. Currently, AbbVie has a market capitalization of $3...
Global drugmakers rush to boost US presence as tariff threat looms
Global drugmakers are scrambling to shore up their U.S. manufacturing capacity and domestic inventory as the Trump administration weighs hefty tariffs on pharmaceutical imports into the country.
AbbVie updates mid-stage trial data for Genmab-partnered lymphoma drug in outpatient setting
AbbVie (ABBV) stock in focus as the company posts new data from a mid-stage trial for its lymphoma drug epcoritamab developed with Genmab. Read more here.
AbbVie Announces Updated Results From Phase 2 EPCORE® NHL-6 Study Evaluating the Potential for Outpatient Monitoring of Epcoritamab in Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
Data presented at 13th Society of Hematologic Oncology (SOHO) Annual Meeting NORTH CHICAGO, Ill. , Sept. 3, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced updated results from the Phase 2 EP...
AbbVie (ABBV) Gains Health Canada Approval for Elahere in Ovarian Cancer
AbbVie (ABBV) Gains Health Canada Approval for Elahere in Ovarian Cancer
AbbVie's Elahere gains approval in Canada for ovarian cancer
AbbVie to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
NORTH CHICAGO, Ill. , Sept. 2, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9, 2025.
Key deals this week: Hawkins, Canada Goose, AbbVie, Verint and more
Discover the latest major acquisitions across industries, including biotech, tech, finance, and energy.
How To Invest $100,000 In A Near-Perfect Strategy Portfolio
Market timing is futile; a disciplined, diversified, and rules-based approach is essential for long-term investing success. A Near-Perfect Strategy portfolio aims for consistent income, growth, and lo...
AbbVie Smashes Earnings, Bets Big On Depression Drug Bretisilocin
J&J halts studies for potential rival to AbbVie’s Humira after trial setback
Johnson & Johnson (JNJ) stock is in focus as the company halts nipocalimab combo therapy for rheumatoid arthritis after a trial failure. Read more here.
Healthcare Stocks Are ‘Priced at Panic Levels.' It's Time to Buy.
They're bargains right now, according to two key measures. Expert Jim Paulsen won't venture a guess when the prices will recover.
Best Dividend Aristocrats For September 2025
Dividend Aristocrats have shown mixed 2025 performance, with some delivering double-digit gains and others lagging, but overall stability remains a hallmark. Dividend growth is robust, with 53 of 69 A...